IDXG — Interpace Biosciences Share Price
0.000.00%
Last trade - 00:00- $2.88m
- $5.70m
- $46.93m
- 51
- 100
- 23
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 0.76 | ||
| Price to Sales | 0.06 | ||
| EV to EBITDA | 0.64 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 194.11% | ||
| Return on Equity | n/a | ||
| Operating Margin | 17.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 32.4 | 33.12 | 31.84 | 40.04 | 46.93 | n/a | n/a | 14.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -20.59 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Directors
- Thomas Burnell PRE (59)
- Thomas Freeburg CFO (53)
- Vijay Aggarwal DRC
- Robert Gorman DRC (63)
- Edward Chan IND (38)
- Joseph Keegan IND (68)
- Fortunato Rocca IND (59)
- Stephen Sullivan IND (74)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 10th, 1998
- Public Since
- May 19th, 1998
- No. of Shareholders
- 184
- No. of Employees
- 111
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,423,093
- Address
- Waterview Plaza, PARSIPPANY, 07054
- Web
- https://www.interpace.com/
- Phone
- +1 4122246100
- Auditors
- EisnerAmper LLP
Upcoming Events for IDXG
Q2 2025 Interpace Biosciences Inc Earnings Release
Similar to IDXG
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
What is the Interpace Biosciences share price?
As of Today at 21:21 UTC, shares in Interpace Biosciences are trading at $0.65. This share price information is delayed by 15 minutes.
How has the Interpace Biosciences share price performed this year?
Shares in Interpace Biosciences last closed at $0.65 and the price had moved by -54.31% over the past 365 days. In terms of relative price strength the Interpace Biosciences share price has underperformed the S&P500 Index by -57.31% over the past year.
What are the analyst and broker recommendations for Interpace Biosciences?
The overall consensus recommendation for Interpace Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Interpace Biosciences dividend yield?
Interpace Biosciences does not currently pay a dividend.
Does Interpace Biosciences pay a dividend?
Interpace Biosciences does not currently pay a dividend.
When does Interpace Biosciences next pay dividends?
Interpace Biosciences does not currently pay a dividend.
How do I buy Interpace Biosciences shares?
To buy shares in Interpace Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Interpace Biosciences?
As of the previous close price of $0.65, shares in Interpace Biosciences had a market capitalisation of $2.88m.
Where are Interpace Biosciences shares listed?
Here are the trading details for Interpace Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: IDXG
What kind of share is Interpace Biosciences?
Based on an overall assessment of its quality, value and momentum Interpace Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Interpace Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Interpace Biosciences is $11.00. That is 1592.31% above the last closing price of $0.65.
Analysts covering Interpace Biosciences currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Interpace Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Interpace Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -75.26%.
As of the last closing price of $0.65, shares in Interpace Biosciences were trading -62.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Interpace Biosciences PE Ratio?
The Interpace Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Interpace Biosciences?
Interpace Biosciences' management team is headed by:
- Thomas Burnell - PRE
- Thomas Freeburg - CFO
- Vijay Aggarwal - DRC
- Robert Gorman - DRC
- Edward Chan - IND
- Joseph Keegan - IND
- Fortunato Rocca - IND
- Stephen Sullivan - IND